Niagen Bioscience, Inc. $NAGE Stock Holdings Boosted by Renaissance Technologies LLC

Renaissance Technologies LLC grew its position in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) by 45.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 1,328,843 shares of the company’s stock after purchasing an additional 414,725 shares during the quarter. Renaissance Technologies LLC’s holdings in Niagen Bioscience were worth $5,860,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of NAGE. New York State Teachers Retirement System bought a new stake in shares of Niagen Bioscience in the 4th quarter worth $30,000. Ameritas Investment Partners Inc. bought a new position in Niagen Bioscience during the third quarter valued at about $45,000. Quantbot Technologies LP bought a new position in Niagen Bioscience during the third quarter valued at about $48,000. Kestra Advisory Services LLC acquired a new position in Niagen Bioscience during the fourth quarter worth about $70,000. Finally, SummitTX Capital L.P. acquired a new position in Niagen Bioscience during the fourth quarter worth about $79,000. Institutional investors own 15.41% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research note on Friday, July 17th. Canaccord Genuity Group lowered their price objective on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday. Finally, Wall Street Zen lowered shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.33.

Niagen Bioscience Stock Performance

Shares of NASDAQ:NAGE opened at $2.96 on Thursday. The company has a market cap of $235.73 million, a PE ratio of 16.45 and a beta of 2.09. Niagen Bioscience, Inc. has a 52 week low of $2.87 and a 52 week high of $11.29. The firm has a 50 day simple moving average of $3.41 and a 200 day simple moving average of $4.34.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. Niagen Bioscience had a net margin of 12.39% and a return on equity of 18.31%. The firm had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. On average, equities analysts predict that Niagen Bioscience, Inc. will post 0.21 earnings per share for the current year.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.